Robert joined BayPAT as Managing Director in January 2017, coming from Lophius Biosciences, a VC-backed clinical-stage biotech company, where he served as CEO. Prior to that he was Head of Business Development and Licensing and member of the management board of SuppreMol, a biopharmaceutical company that has been acquired by Baxalta for EUR 200 million in 2015.
Robert is a biochemist by training and is a Certified Licensing Professional (CLP) and a Registered Technology Transfer Professional (RTTP). He has more that 20 years of experience in the life sciences industry, over 15 years of which in the area of business development and licensing.
Robert received his PhD in Biochemistry from the University of Frankfurt and the Paul-Ehrlich-Institute, the German Federal Institute for Vaccines and Biomedicines and held a research position as a post-doctoral fellow at the Medical University of South Carolina, USA. He currently serves as a board member of MODAG GmbH.